CAI Seminar Series: Molecular Pharmacology of Cannabinoid Receptor 2, a Promising Therapeutic Target
Event Details
Event Contact
Event Description
- Full Description:
- Dr Natasha Lillia Grimsey, Department of Pharmacology and Clinical Pharmacology
and Centre for Brain Research, School of Medical Sciences, Faculty of Medical and Health Sciences, joins us from The University of Auckland, New Zealand, to present:
Molecular Pharmacology of Cannabinoid Receptor 2, a Promising Therapeutic Target
Cannabinoid Receptor 2 (CB2) is a G protein-coupled receptor (GPCR) with considerable, though as-yet unrealised, therapeutic potential. Predominantly expressed in the immune system, CB2 activation is associated with immune suppression, and is thus of particular interest as a therapeutic target in a diverse range of disorders involving immune system over-activation. Although expressed at only a low level in the healthy brain, CB2 is upregulated in neuroinflammation and thought to be a promising target.
CB2 is under-studied in comparison with many other GPCRs. I will discuss my lab’s current efforts to further our understanding of CB2 molecular pharmacology in a variety of aspects. CB2 is observed to be expressed both on the cell surface and intracellularly, and exhibits an unusual trafficking response to orthosteric ligands; we are investigating control of this trafficking, and influences on signalling. I will also report on our findings regarding the functional impact of non-synonymous single nucleotide polymorphisms (SNPs) and differences in pharmacology between human and rodent CB2 – both of which provide challenges and opportunities for developing CB2 as a therapeutic target.
Register for this webinar: https://cai.centre.uq.edu.au/event/session/2159
(Zoom details automatically provided upon registration)
Event Tools
Share This Event
Print
Email
Share
Rate This Event
Tweet This Event
Calendar Tools
Featured Calendars
Subscribe via RSS